Understand the source comparison
Mechanism Comparison: How ARA-290 Alternatives Work Differently
ARA-290 (reference) Innate repair receptor activation IRR/CD131 Broad (neural, vascular, epithelial) 3–5 hours 2–8°C refrigerated 1–10 mg/kg BPC-157 VEGF receptor modulation + NO stabilization Angiogenesis, fibroblast migration GI tract, tendons, vasculature 4
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- ARA-290 (reference)
- Innate repair receptor activation
- IRR/CD131
- Broad (neural, vascular, epithelial)
- 3–5 hours
- 2–8°C refrigerated
- 1–10 mg/kg
- BPC-157
- VEGF receptor modulation + NO stabilization
- Angiogenesis, fibroblast migration
- GI tract, tendons, vasculature
- 4–6 hours
- 200–500 mcg/kg
- TB-500
- Actin polymerization regulation
- Cytoskeletal remodeling, cell migration
- Muscle, cardiac, neural
- 3–4 days
- -20°C frozen (pre-mix)
- 2–10 mg/week
- Thymalin
- Thymic peptide regulation
- T-cell differentiation, immune homeostasis
- Thymus, lymphoid tissue
- 2–3 hours
- 5–20 mcg per cycle
- Professional Assessment
- BPC-157 is the closest functional substitute for ARA-290 in gastrointestinal and vascular injury models. It shares overlapping endpoints (reduced inflammation, accelerated healing) despite working through growth factor pathways rather than IRR activation. TB-500 excels in structural tissue repair applications where cell migration is rate-limiting. Thymalin addresses immune-mediated regeneration that ARA-290 influenced indirectly through IRR's anti-inflammatory effects.
- The table clarifies a critical point: none of these ara-290 alternatives 2026 best peptides activate the innate repair receptor. ARA-290's uniqueness was its ability to trigger tissue protection without hematopoietic side effects. A receptor selectivity no current alternative replicates exactly. What BPC-157, TB-500, and Thymalin offer instead is mechanistic diversity: multiple pathways converging on similar experimental outcomes. Labs transitioning from ARA-290 protocols often combine two alternatives rather than relying on a single substitute. For example, pairing BPC-157's angiogenic effects with Thymalin's immune modulation to recapitulate the multi-system protection ARA-290 provided through IRR activation alone.